Clinical Trial Update: Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of HBI-002, a low-dose carbon monoxide therapy, to evaluate safety, tolerability, pharmacokinetics, and biomarkers in Parkinson's disea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• HBI-002

Snippet

Sponsor: Hillhurst Biopharmaceuticals, Inc. | Conditions: Parkinson Disease | Phase 2 | Status: NOT_YET_RECRUITING